A 39-year-old patient presents with urinary frequency and dysuria; dipstick analysis is negative for leukocytes and nitrates but positive for hematuria. What is the appropriate next step in evaluation and management?

Confirm Microscopic Hematuria with Formal Urinalysis Before Proceeding

The immediate next step is to obtain a formal microscopic urinalysis to confirm the presence of ≥3 red blood cells per high-powered field (RBC/HPF), as dipstick testing alone is insufficient to guide further evaluation 1.

Critical First Step: Microscopic Confirmation

The dipstick hematuria finding must be verified before initiating any downstream workup. According to the American College of Physicians guidelines, clinicians should confirm heme-positive dipstick results with microscopic urinalysis demonstrating ≥3 erythrocytes per high-powered field before initiating further evaluation 1. This is essential because:

• Dipstick testing has false-positive rates from myoglobinuria, hemoglobinuria, or other substances
• Only microscopically confirmed hematuria (≥3 RBC/HPF) warrants urologic evaluation
• Recent data shows 31% of positive dipsticks are never followed by confirmatory microscopy, leading to inappropriate testing or missed diagnoses 2

Addressing the Clinical Presentation

While awaiting microscopic confirmation, note that this patient has dysuria and frequency with negative leukocytes/nitrites—an atypical pattern for simple urinary tract infection. This combination raises several considerations:

• Absence of pyuria (negative leukocytes) makes bacterial cystitis less likely 3
• The symptoms could represent urethritis, bladder irritation from stones, or early bladder pathology
• Do not dismiss hematuria simply because UTI markers are negative—this patient still requires full evaluation if microscopy confirms ≥3 RBC/HPF

Risk Stratification After Confirmation

Once microscopic hematuria is confirmed (≥3 RBC/HPF), immediately stratify the patient's risk using the 2025 AUA/SUFU criteria 4:

High-risk factors include:

• Age >50 years (this patient is 39, so intermediate risk by age alone)
• Smoking history (≥10 pack-years)
• History of gross hematuria
• Male sex
• Occupational exposures (aromatic amines, benzene)
• History of pelvic radiation
• Chronic irritation (indwelling catheter, stones)

This 39-year-old would be classified as intermediate-risk at minimum, requiring cystoscopy and upper tract imaging 4.

Subsequent Evaluation Pathway

If microscopy confirms ≥3 RBC/HPF:

1. Ask specifically about any history of gross hematuria—even self-limited episodes warrant full urologic evaluation 1

2. Assess for glomerular vs. non-glomerular source:

   • Check for proteinuria, dysmorphic RBCs, RBC casts, elevated creatinine
   • If present, concurrent nephrology referral is needed 5
   • Normal RBC morphology suggests urologic (non-glomerular) source

3. Refer to urology for:

   • Cystoscopy to evaluate bladder and urethra
   • Upper tract imaging (multiphasic CT urography preferred) 4, 6
   • Do not obtain urine cytology or molecular markers in initial evaluation—these are not recommended 1

Common Pitfalls to Avoid

• Never treat presumptively for UTI without pyuria when hematuria is present—the negative leukocytes/nitrites make infection unlikely, and empiric antibiotics may delay cancer diagnosis
• Do not skip microscopic confirmation—69% of patients receive confirmatory microscopy, but 31% proceed to imaging without it, resulting in unnecessary procedures 2
• Do not reassure and discharge based on negative infection markers alone—up to 5% of patients with asymptomatic microscopic hematuria have urinary tract malignancy 6
• Persistent hematuria after treating a concurrent UTI still requires full urologic evaluation 6

If Microscopy is Negative (<3 RBC/HPF)

If formal microscopy shows <3 RBC/HPF, the patient does not meet criteria for hematuria evaluation. Address the dysuria and frequency through alternative diagnoses (urethritis, interstitial cystitis, bladder irritants) 7.